Mitazalimab (ADC-1013)
1st line metastatic pancreatic ductal adenocarcinoma (PDAC)
Key Facts
Indication
1st line metastatic pancreatic ductal adenocarcinoma (PDAC)
Phase
Phase 2
Status
Active
Company
About Alligator Bioscience AB
Alligator Bioscience is dedicated to developing innovative antibody-based cancer immunotherapies. The company's core strategy revolves around its proprietary technology platforms designed to generate highly specific and potent antibodies. Its most advanced asset, mitazalimab (a CD40 agonist), is being evaluated in a pivotal Phase 2 trial for metastatic pancreatic cancer, a significant unmet medical need. The company also has a strategic partnership with Orion Corporation for the development of bispecific antibodies and collaborates with other biopharmaceutical firms.
View full company profileTherapeutic Areas
Other 1st line metastatic pancreatic ductal adenocarcinoma (PDAC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mitazalimab + chemotherapy | Alligator Bioscience AB | Phase 1b/2 |